JP2005506331A5 - - Google Patents

Download PDF

Info

Publication number
JP2005506331A5
JP2005506331A5 JP2003530327A JP2003530327A JP2005506331A5 JP 2005506331 A5 JP2005506331 A5 JP 2005506331A5 JP 2003530327 A JP2003530327 A JP 2003530327A JP 2003530327 A JP2003530327 A JP 2003530327A JP 2005506331 A5 JP2005506331 A5 JP 2005506331A5
Authority
JP
Japan
Prior art keywords
antibody
use according
aglycosylated
origin
rat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003530327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506331A (ja
JP4694784B2 (ja
Filing date
Publication date
Priority claimed from GB0123156A external-priority patent/GB2380127A/en
Application filed filed Critical
Publication of JP2005506331A publication Critical patent/JP2005506331A/ja
Publication of JP2005506331A5 publication Critical patent/JP2005506331A5/ja
Application granted granted Critical
Publication of JP4694784B2 publication Critical patent/JP4694784B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003530327A 2001-09-26 2002-09-26 慢性関節炎の処置 Expired - Fee Related JP4694784B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0123156.2 2001-09-26
GB0123156A GB2380127A (en) 2001-09-26 2001-09-26 Treatment of chronic joint inflammation
PCT/GB2002/004358 WO2003026692A2 (en) 2001-09-26 2002-09-26 Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex

Publications (3)

Publication Number Publication Date
JP2005506331A JP2005506331A (ja) 2005-03-03
JP2005506331A5 true JP2005506331A5 (enExample) 2007-08-02
JP4694784B2 JP4694784B2 (ja) 2011-06-08

Family

ID=9922741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003530327A Expired - Fee Related JP4694784B2 (ja) 2001-09-26 2002-09-26 慢性関節炎の処置

Country Status (10)

Country Link
US (1) US20050037004A1 (enExample)
EP (3) EP1803466B1 (enExample)
JP (1) JP4694784B2 (enExample)
AU (2) AU2002329423B2 (enExample)
CA (1) CA2461714C (enExample)
DE (1) DE60217698T2 (enExample)
ES (2) ES2279884T3 (enExample)
GB (1) GB2380127A (enExample)
PT (1) PT1432445E (enExample)
WO (1) WO2003026692A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
US6660948B2 (en) * 2001-02-28 2003-12-09 Vip Investments Ltd. Switch matrix
MY154009A (en) 2002-03-13 2015-04-30 Biogen Idec Inc Anti-alpha v beta 6 antibodies
EP1664116A4 (en) * 2003-08-22 2009-06-03 Biogen Idec Inc IMPROVED ANTIBODIES WITH CHANGED EFFECTOR FUNCTION AND MANUFACTURING METHOD THEREFOR
EP2397189B1 (en) 2003-11-14 2015-03-18 Brigham and Women's Hospital, Inc. Methods of modulating immunity
PT1737490E (pt) * 2004-04-06 2010-08-31 Novimmune Sa Processos de tratamento da aterosclerose
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
RU2271816C1 (ru) * 2004-07-08 2006-03-20 Григорий Менделевич Дубровин Способ профилактики посттравматического остеоартроза
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
US7740856B2 (en) 2005-12-20 2010-06-22 Isu Abxis Co., Ltd. Effect of BST2 on inflammation
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
WO2007009064A2 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007117600A2 (en) * 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
WO2007147090A2 (en) * 2006-06-14 2007-12-21 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
SG173364A1 (en) 2006-07-10 2011-08-29 Biogen Idec Inc Compositions and methods for inhibiting growth of smad4-deficient cancers
EP2170951A2 (en) * 2007-05-31 2010-04-07 Genmab A/S Recombinant non glycosylated monovalent half-antibodies obtained by molecular engineering
WO2010132872A1 (en) * 2009-05-15 2010-11-18 Novimmune S.A Combination therapies and methods using anti-cd3 modulating agents and anti-tnf antagonists
CA2778334A1 (en) * 2009-10-20 2011-04-28 Charlotte Mckee Anti-cd3 antibody dosing in autoimmune disease
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US20220372148A1 (en) 2019-07-05 2022-11-24 Ono Pharmaceutical Co., Ltd. A pharmaceutical composition for treating hematological cancer
US12122850B2 (en) 2022-03-14 2024-10-22 LamKap Bio gamma AG Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183657A (en) 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DK0610447T3 (da) 1991-10-15 1999-08-23 Btg Int Ltd CDw52-specifikt antistof til behandling af T-cellemedieret inflammation af leddene
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
SE510197C2 (sv) 1997-02-06 1999-04-26 Asea Brown Boveri Förfarande och anordning för styrning av ett kondensatordon för en shuntkopplad statisk kompensatorenhet med deblockeringssignaler för indikering av icke strömförande tillstånd hos ingående ventiler
US5843597A (en) * 1997-12-01 1998-12-01 Eveready Battery Company, Inc. Ribbed gasket for miniature galvanic cell
CA2224256C (en) * 1997-12-09 2013-04-30 I.N.S.E.R.M. Method for treating established spontaneous auto-immune diseases in mammals
GB9815909D0 (en) * 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
AUPQ431299A0 (en) * 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance

Similar Documents

Publication Publication Date Title
JP2005506331A5 (enExample)
JP2009539841A5 (enExample)
JP2004536072A5 (enExample)
JP2020002172A5 (enExample)
JP2013508392A5 (enExample)
CN111630070A (zh) 三特异性蛋白质及使用方法
JP2014114288A5 (enExample)
DE05075555T1 (de) Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern
JP2013518912A5 (enExample)
JP2014533279A5 (enExample)
RU2018100129A (ru) Способы лечения подагры
CN105251004A (zh) 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物
CN105705518A (zh) 用于治疗类风湿性关节炎或作为镇痛药的中和gm-csf的抗体
JP2019532970A5 (enExample)
Choy et al. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti‐CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients
JP2019218359A (ja) Gd2陽性がんを処置するための製剤および方法
JP2017031209A (ja) アタシセプトなどのTACI−Ig融合タンパク質を用いた自己免疫疾患を治療するための投薬法
JP2023138982A (ja) インターロイキン-17(il-17)アンタゴニストを使用して腱障害を治療する方法
BR112020017445A2 (pt) anticorpos anti cd6 para tratar asma severa
JP2018532693A5 (enExample)
CA2074662A1 (en) Anti-idiotypic antibodies that mimic tnf
RU2006113701A (ru) Лечение респираторных заболеваний антителами против рецептора il-2
CN109641953A (zh) 针对il-17a、il-17f和其他促炎性分子的三特异性抗体
TW202120546A (zh) 使用介白素-17(il-17)拮抗劑治療狼瘡性腎炎之方法
AU756167B2 (en) Application of TNF antagonists as medicaments for treating septic diseases